Skip to Content

Modeling and Simulation of Chimeric Antigen Receptor (CAR) T Cell Therapy

FDA/CBER, Office of Biostatistics and Epidemiology, Silver Spring, Maryland

Position Description:

An ORISE research fellowship is available immediately at the Food and Drug Administration (FDA) in Silver Spring, Maryland. The successful candidate will participate in the development of a quantitative key event relationships model to simulate and predict immune responses of Chimeric Antigen Receptor (CAR) T cells. The end goal of this project is the development of a computational tool to enhance efficacy and safety evaluation of current and next-generation of engineered therapeutic products, leading to personalized, optimal treatment regimens for patients undergoing CAR T cell therapy. Under the guidance of a mentor, the participant will help develop and apply novel techniques to model and simulate interactive cellular components of CAR T Cells, as well as perform literature review, data collection/database curation, model development, presentation of research results, and preparation of scientific manuscripts.

This position is a post-doctoral fellowship through the Oak Ridge Institute for Science and Education (ORISE).


The qualified candidate should have received a doctoral degree in one of the relevant fields or be currently pursuing the degree and will reach completion by June 1, 2019. Degree must have been received within five years of the appointment start date. This position is only open for US citizens, permanent residents (Green Card holders) or individuals residing in US for 3 years during the last 5 years on a valid US visa. Preferred skills/experience are

  • knowledge of immunology, modeling and programming skills,
  • experience with differential equations,
  • excellent written and oral communication skills,
  • solid background and skills in both biology and computing science

Candidates will be offered competitive salary and health benefits.

To Apply:

Highly motivated candidates should apply through (Reference Code: FDA-CBER-2019-0022)